Johnson & Johnson Assumes Full Sales and Marketing Control of Inflammatory Disease Medications
Johnson & Johnson (J&J) has officially taken over all sales, marketing, and distribution responsibilities for two major anti-inflammatory medications, Remicade (infliximab) and Simponi (golimumab), within the UK.
This move marks a significant shift in the commercial landscape for these treatments, which have provided essential care options for millions managing complex inflammatory conditions.
For over 25 years, infliximab has been a crucial component in treating various inflammatory diseases, including rheumatoid arthritis (RA), Crohn’s disease (CD), paediatric CD, ulcerative colitis (UC), paediatric UC, radiographic axial spondyloarthritis (also known as ankylosing spondylitis), psoriatic arthritis (PsA), and psoriasis.
Likewise, golimumab has been a reliable treatment option for RA, polyarticular juvenile idiopathic arthritis, PsA, radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, and UC for more than a decade.
Together, these medications have played an essential role in transforming the lives of patients suffering from debilitating inflammatory conditions.
Merck Sharp & Dohme (UK) Limited (MSD), the former commercialising partner for infliximab and golimumab in the UK, ceased its involvement as of October 1, 2024. As part of this transition, J&J’s subsidiary Janssen-Cilag Ltd assumed responsibility for the products, allowing J&J to integrate infliximab and golimumab seamlessly into its already robust immunology portfolio.
This addition signifies J&J’s dedication to enhancing its support for patients and healthcare providers within the immunology sector, furthering its mission to deliver trusted, effective healthcare solutions.
In collaboration with MSD, J&J executed a smooth transition, ensuring that patients relying on these vital treatments experienced no disruption in their care. The two companies coordinated efforts meticulously to ensure continuous supply and maintain high standards of patient care throughout the handover.
To conclude, this strategic move by Johnson & Johnson strengthens its immunology offerings and reinforces its commitment to providing dependable healthcare solutions for those affected by life-changing inflammatory diseases.
With this new role, J&J continues its journey to support UK patients and healthcare providers, meeting the needs of individuals battling chronic inflammatory conditions with stability and excellence.
News Credits: Johnson & Johnson expands treatment options for inflammatory diseases
Things you may also like: